Should I buy or sell Pieris Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PIRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PIRS, but not buy additional shares or sell existing shares. View PIRS analyst ratings or view top-rated stocks .

How have PIRS shares performed in 2024?

Pieris Pharmaceuticals' stock was trading at $0.1820 at the beginning of 2024. Since then, PIRS shares have decreased by 20.3% and is now trading at $0.1450. View the best growth stocks for 2024 here .

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 134,100 shares, an increase of 222.4% from the March 15th total of 41,600 shares. Based on an average trading volume of 590,900 shares, the short-interest ratio is presently 0.2 days. View Pieris Pharmaceuticals' Short Interest .

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PIRS earnings forecast .

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its earnings results on Friday, March, 29th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company earned $1.30 million during the quarter. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 90.17% and a negative net margin of 57.33%.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM) , TG Therapeutics (TGTX) , Corbus Pharmaceuticals (CRBP) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Amarin (AMRN) , Dynavax Technologies (DVAX) , Sangamo Therapeutics (SGMO) , Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL) .

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PIRS Stock Alerts

$0.14

-0.01 (-6.63%)

(As of 04:00 PM ET)

Compare

Today's Range: $0.14
▼
$0.16
50-Day Range: $0.16
▼
$0.22
52-Week Range: $0.14
▼
$1.01

Volume: 1.92 million shs
Average Volume: 580,149 shs
Market Capitalization: $14.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Pieris Pharmaceuticals alerts:

Ad Behind the Markets

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

Click here to learn more >>>

About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

PIRS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PIRS Stock News Headlines

April 13, 2024 | americanbankingnews.com

StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

April 1, 2024 | msn.com

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 28, 2024 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

March 27, 2024 | finance.yahoo.com

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

March 19, 2024 | finance.yahoo.com

PIRS Apr 2024 2.500 call

February 10, 2024 | investing.com

Pieris Pharmaceuticals Inc (PIRS)

February 1, 2024 | finance.yahoo.com

Pieris Pharmaceuticals, Inc. (PIRS)

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

December 18, 2023 | finance.yahoo.com

Investors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%

November 20, 2023 | investing.com

Pieris Pharmaceuticals Inc (PIRS) Earnings Dates & Reports

November 4, 2023 | morningstar.com

Pieris Pharmaceuticals Inc PIRS

September 25, 2023 | finance.yahoo.com

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why

August 24, 2023 | finance.yahoo.com

Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis

August 23, 2023 | finance.yahoo.com

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know

August 18, 2023 | msn.com

Pieris (PIRS) Up On Receiving Milestone Payment From Partner

August 17, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

July 19, 2023 | finance.yahoo.com

Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises

July 19, 2023 | markets.businessinsider.com

Pieris Pharma Cuts Around 70% Workforce; Plans Strategic Options

July 18, 2023 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

July 18, 2023 | finance.yahoo.com

Why Pieris Pharmaceuticals Shares Shooting Higher Today?

July 18, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

July 13, 2023 | fool.com

Pieris Pharmaceuticals (NASDAQ: PIRS)

June 21, 2023 | msn.com

Why Are Pieris Pharmaceuticals Shares Tanking Today

June 21, 2023 | finance.yahoo.com

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

June 11, 2023 | finance.yahoo.com

We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

June 2, 2023 | finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

See More Headlines

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PIRS
CUSIP: N/A
CIK: 1583648
Web: www.pieris.com
Phone: (857) 246-8998
Fax: 49-8161-141-1444
Employees: 127
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,540,000.00
Net Margins: -57.33%
Pretax Margin: -57.33%
Return on Equity: -90.17%
Return on Assets: -38.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.24
Quick Ratio: 3.24

Sales & Book Value

Annual Sales: $42.81 million
Price / Sales: 0.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.27 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 98,930,000
Free Float: 90,140,000
Market Cap: $15.33 million
Optionable: Optionable
Beta: 0.48

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Stephen S. Yoder J.D. (Age 48)
CEO, President & Director
Comp: $774.72k
Mr. Thomas Bures (Age 49)
Senior VP, CFO & Treasurer
Comp: $499.38k
Maria Kelman
Executive Director of Investor Relations
Dr. Shane Olwill Ph.D. (Age 48)
Senior VP & Chief Development Officer
Mr. Prompong Chaikul (Age 37)
Chief Supply Chain Officer
Dr. Florian Witte Ph.D.
VP and Head of Alliance Management & Early Project Leadership

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PIRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pieris Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PIRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PIRS, but not buy additional shares or sell existing shares.
View PIRS analyst ratings or view top-rated stocks.
How have PIRS shares performed in 2024?: Pieris Pharmaceuticals' stock was trading at $0.1820 at the beginning of 2024. Since then, PIRS shares have decreased by 20.3% and is now trading at $0.1450.
View the best growth stocks for 2024 here.
Are investors shorting Pieris Pharmaceuticals?: Pieris Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 134,100 shares, an increase of 222.4% from the March 15th total of 41,600 shares. Based on an average trading volume of 590,900 shares, the short-interest ratio is presently 0.2 days.
View Pieris Pharmaceuticals' Short Interest.
When is Pieris Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PIRS earnings forecast.

How were Pieris Pharmaceuticals' earnings last quarter?: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its earnings results on Friday, March, 29th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company earned $1.30 million during the quarter. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 90.17% and a negative net margin of 57.33%.
What other stocks do shareholders of Pieris Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).
How do I buy shares of Pieris Pharmaceuticals?: Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PIRS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial